

Alzheimer's disease and the Possible role of vitamin D

Abstract:

Alzheimer's disease (AD) is a neurological illness that causes dementia. Despite the enormous global economic cost and impact on patients' immediate family members, there is no definitive cure, necessitating the development of improved therapeutic options. While memory and cognition are significantly impaired with Alzheimer's disease, the actual cause remains unknown. Among well-known hypotheses used to explain AD pathophysiology is Amyloid (A β) plaque development and aggregation hypothesis. There are now five FDA-approved medications that are used as therapy alternatives. All medications are used to treat symptoms of Alzheimer's disease. So, disease modifying treatments that target the AD pathological changes, are required. Those treatments may targeting suppression of the pathogenesis pathways. Vitamin D is generated in human epithelial cells through the photochemical formation and is also obtained through dietary resources. Calcium homeostasis and bone metabolism are two of the most well-known vitamin D impacts. Aside from that, non-traditional vitamin D benefits have recently acquired popularity. Vitamin D regulates the growth and activities of the central nervous system, which is an important but less understood function of the vitamin. Vitamin D's neuroprotective properties are associated with its effects on neurotrophin creation and secretion, neuromodulator synthesis, intracellular calcium homeostasis, and avoidance of oxidative nerve damage. The protective and therapeutic effects of vitamin D on neurodegenerative diseases are not intensively investigated

In this review, a comprehensive approach to understanding the pathogenesis of AD and the possible role of vitamin D in the protection and therapeutic of AD will be addressed.

Key words:

Alzheimer's disease, Central nervous system, Vitamin D, Genetic, Pathophysiology, Protection.

Comment [A1]: Acronyms are not defined in the abstract. If an acronym is defined, the words to which the defined acronym refers should no more be used. (AD)

Comment [A2]: In the abstract you should focus on the role of vitamin D in Alzheimer's disease to develop the abstract, it is the most important idea in the abstract so it cannot be the shortest.

Comment [A3]: The objective of a research is not written in the future tense. Write in the past or present tense, I recommend the past.

Introduction

Neurodegenerative disorders characterized by a gradual reduction of nerve cell functions or structure that may lead to neuron death. Neurodegenerative diseases included Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) (1). These disorders are considered incurable, and they cause a progressive decline in health to the point that neurons die. AD is commonest type of neurodegenerative disorders, about 75% of neurodegenerative cases (2)

The pathogenic hallmarks of Alzheimer's disease are thought to be aggregation of abnormal proteins in the brain, as amyloid beta ($A\beta$) and tau protein derivatives, then oxidative stress destruction and inflammations that caused disturbance in energy metabolism, localized synapsis failure, and deaths of the neurons (3).

Many licensed medications for Alzheimer's disease try to improve cognitive and reduce behavioral symptoms, however they only provide minor advantages to patients (Shen, 2022). As a result, there is more interest in non-pharmacological therapy to help people with Alzheimer's disease and their caregivers cope with their symptoms (4).

The association between vitamin D and brain functions was discovered by researchers. The presence of receptors of vitamin D in the central nervous system suggests that vitamin D plays an essential role in the CNS, altering how people think, react, and learn. Some researchers refer to vitamin D as the “forgotten neurosteroid” (5). Vitamin D also plays a significant function in reducing oxidative stress by increasing gene expression that code for antioxidant enzymes (6). Vitamin D has neuroprotection, neurotrophs, neurotransmission, and neuroplasticity roles in the brain, so vitamin D deficiency may play role in dementia and AD progression (7). Low levels of vitamin D associated with neurodegeneration disorders as Alzheimer's and Parkinson's diseases (8).

Aim of this review was to summarize the mechanisms underlying Alzheimer's disease, shed light on the neuroprotective effects of vitamin D, association between vitamin D and Alzheimer's disease, and review possible potential vitamin D protective effects to Alzheimer's disorder.

Study design:

Comment [A4]: It can be written in a more concrete way and still contain the main idea of the research.

A systematic search of PubMed and Google scholar databases was made to retrieve the studies published about association between vitamin D and neurodegenerative diseases especially Alzheimer disease. The terms used for the PubMed and Google Scholar search are Neurogenerative diseases, Alzheimer disease, vitamin D protective effect, vitamin D therapeutic effect. The current search included studies conducted in humans, and animals and was restricted to English published researches. We also screened the reference lists of reviews and included the related researches in these lists.

Comment [A5]: Google scholar is not a database.

Comment [A6]: You should not make citations for articles that you did not use, much less review.

Pathogenesis of AD

Alzheimer's disease is commonest neurodegenerative illness with about 50 million person had AD disease (9). In Alzheimer's disease neurons die irreversibly, especially in hippocampus and cortex. It is characterized by decline cognitive functioning (visuospatial issues, memory, and executive functioning), emotional control, and neuropsychiatric manifestations as apathy, depression, and agitation (2). The diagnosis of AD based upon neurological examination and elimination of other causes of dementia; only an autopsy provides a definite diagnosis. Neuronal loss, brain atrophy, extracellular collection of senile plaques containing the peptide A β and neurofibrillary tangles (NFTs) made from hyperphosphorylated tau proteins, as well as loss of synapses and neurotransmission dysfunctions are all symptoms of Alzheimer's disease. (10), as well as neuroinflammation (11) are pathogenic markers of AD.

Various mechanisms of neurodegeneration emerged, as amyloid plaque accumulation, inflammatory reactions, neurofibrillary degenerations, excitotoxicity of glutamate neurotransmitters, increased intraneuronal influx of calcium, oxidative stress reactions and mitochondrial dysfunctions, despite the fact that the pathophysiological a etiology of AD is unknown (12).

It is still unclear what causes Alzheimer's disease in the vast majority of cases, except for a few of them where genetic abnormalities have been identified. By cleaving amyloid precursor protein (APP), neurotoxic A is produced, and senile plaques, a prominent neuropathological stigmata of AD, are made by the aggregation of soluble oligomers (13). As previously mentioned, APP serves as two enzymes substrates. They are α -secretase and β -secretase, respectively. The two enzymes split APP's extracellular domain, resulting in 2 soluble N-terminal peptides, APPs α and APPs β , and C-terminal

fragments CTF α and CTF β attached to membrane of cells. Proteolysis occurs next. A third enzyme, γ -secretase, cleaves the transmembrane peptides CTF α and CTF β inside membrane. This leads CTF α to release the p3 peptide and amyloid β (A β) into the extracellular space. The soluble peptide p3 shows no tendency to agglomerate. In contrast, amyloid β prefers to clump together (14, 15). Amyloid- β has 40–42 amino acids. This differs because of site alteration at which γ -secretase cleaves protein chain (16). A(1–42) is the most damaging form, as it accumulate and adheres to amino3-hydroxy-5-methyl- 4-isoxazolepropionic acid(AMPA)) receptors (receptor of glutamate) and Ca²⁺ channels, raising Ca²⁺ inflow and intracellular Ca²⁺ levels (17). This leads local inflammatory reactions to neuronal cells apoptosis and death (18). A generates hydrogen peroxide during aggregation process, that potentiated by Cu²⁺ and Fe²⁺ ions. Electrochemically active Cu²⁺ ions trapped inside A β were capable of creating reactive oxygen species (ROS) (19). The lipids peroxidation in neuronal cell membranes caused by these ROS causes glucose transporters and ion channel ATPases to malfunction. Because of oxidative stress generated by A β , the neurons' ion balance and metabolism are disrupted, making them vulnerable to death (13). The creation of aggregates known as neurofibrillary tangles (NFTs) caused by tau protein hyperphosphorylation, a structural protein linked with cytoskeleton of neurons. These factors result in hampered neuron transmission and, eventually, neuron death (20) (Fig. 1).




Fig. 1. Diagram showing insoluble amyloids β formation from amyloid precursor protein (APP) (13).

Vitamin D and neuroprotection

Vitamin D can be produced inside the body. It regulates calcium-phosphorus metabolism and has a variety of biological functions, including brain function and immune response modulation (21-23). Vitamin D is made by irradiating a cutaneous molecule, 7-dehydrocholesterol (7-DHC), with ultraviolet B (UVB) rays. When UVB photons interact with 7-DHC, they make cholecalciferol, which requires two hydroxylation processes to become active form of vitamin D. The hydroxylation first takes place in the liver, where a 25 hydroxylase produces 25(OH)D, but the second hydroxylation is mostly dependent on the kidney 1,25 hydroxylase, which generates 1,25(OH)₂D. Vitamin D's active form also created in a varies tissues, as brain, lung, placenta, prostate, and cells of immune system (24, 25). Vitamin D binding protein (VDBP) carried 25(OH)D and 1,25(OH)₂D from kidney and liver to other tissues, where active form of vitamin D combines with nuclear vitamin D receptor (VDR), resulting in non- genomic and genomic effects (21, 26, 27).

The presence of the enzyme 25(OH)D3-1 α -hydroxylase, which produces the active form of vitamin D, and VDR in the CNS, mainly in hypothalamus and dopaminergic neurons of the substantia nigra of the basal ganglia, indicate that vitamin D has both paracrine and

autocrine actions on CNS function (28). A growing interest in vitamin D effects on CNS led many researchers to investigate 25(OH)D circulating values in AD patients (29-35).

Vitamin D's active form linked to alterations in the formation and release of neurotrophic factors as nerve growth factor (NGF), which is essential for neuron development, and increased values of glial cell line-derived neurotrophic factor (GDNF). When vitamin D is given to hippocampus neurons, it greatly increases rate of neurons outgrowth (36). Also, 1,25-(OH)₂ D₃ modifying acetylcholine synthesis *via* increased enzyme choline acetyltransferase (CAT) gene expression (37). Vitamin D affects GABA-ergic neurotransmission genes expression (38) and enhanced tyrosine hydroxylase (TH) expression, essential for catecholamine generation (39). The production of proteins that bind calcium (Ca²⁺) ions (e.g., parvalbumin) and maintain homeostasis of cellular calcium, which is essential for CNS cell functions, is one of vitamin D's neuroprotective effects (40). Elevated calcium in nerve cells leads to excitotoxicity due to enhancement release of stimulating amino acids, and other stimulating neurotransmitters, nitric oxide synthase (NOS) activation, reactive oxygen species (ROS) generation, proteases and lipases enhancement that leads to plasmic and mitochondrial membrane destruction. A disturbed in calcium ion transport and high calcium values stimulates lipid peroxidation and arachidonic acid pathway (40).

Evidence revealed that vitamin D might protect against cognitive decline by its effects on neurotransmission, neuroprotection, synaptic plasticity, immune modulation, neuronal calcium regulation, and enhanced nerve conduction (41, 42), with secondary protective effects on vascular systems and modifying vascular risk factors (43). *In vitro* studies showed that treatment with vitamin D had anti-inflammatory action by inhibiting interleukin (IL)-6 and tumor necrosis factor (TNF)- α generation (44) (Fig. 2). In this respect, Azhari and Maimanee (45) conducted cross section study on 343 females (18 to 59 years old) from King Abdul Aziz University, Jeddah, Saudi Arabia and measured their serum levels of 25-hydroxyvitamin D and assessed their cognitive levels using Brief Cognitive Status Exam (BCSE). They found that serum 25-hydroxyvitamin D levels were significantly correlated with cognitive status and severely deficient 25-hydroxyvitaminD was independent predictors for cognitive defect.

Comment [A7]: I recommend not to combine risks with benefits. They may address only the role of vitamin D in Ca⁺⁺ absorption or else in antioxidant pathway gene expression.




Fig. 2 Relation between amyloid β pathology and vitamin D in Alzheimer's disease (46).

Genetic association between AD and vitamin D

From 1998 until first decade of 2000s, different chromosome 12 loci were thought to be risk loci for Alzheimer's disease (47-51). The location is significant because VDR gene is also found in same place. VDR gene variant increase risk of Alzheimer's disease by 2 to 3 times (52). Based on a genome-wide association study that enrolled 518 AD cases and 555,000 single nucleotide polymorphisms, Beecham et al. revealed that among a number of proximal candidate genes in 12q13 area, VDR is most likely genetic risk factor for AD (SNPs) (51). SNPs in VDR gene hypothesized to cause some alterations in vitamin D-VDR pathway (52-54). With the rs2228570 exception, none of the SNPs in VDR gene have a functional action (FokI site). Exon 2 of VDR gene has rs2228570, that results in a three-amino-acid elongated version of VDR (55). Intron 8 of VDR gene has rs1544410 (BsmI site), rs7975232 (ApaI site), and rs757343 (Tru9I site) SNPs. The other SNP, rs731236 (TaqI site), present in exon 9 of VDR gene. The intronic SNPs believed to be in strong linkage disequilibrium with SNPs in 3' untranslated region, which included in VDR gene expression regulation (55).

Researches made over past 15 years revealed link between VDR polymorphisms and cognitive decline (56, 57), Alzheimer disease (52, 54, 58), and Parkinsonism (59, 60). Researches revealed that SNPs of megalin (low-density lipoprotein receptor-related protein 2-LRP2), a cell membrane vitamin D transporter, linked with Alzheimer's disease (61, 62) and cognitive decline (57). Although, these researches strongly suggest role in genetic background of neurodegenerative diseases of genes related to vitamin D

metabolism, transport and receptors, more studies required to fully investigate the issue (Fig 3).




Fig. 3 Hypothesis of association between vitamin D receptor (VDR) and Aβ-induced neurodegeneration (63).

Vit D status and risk of AD

As the population continues to age, it is more important to identify modifiable risk factors for Alzheimer's disease in terms of lifestyle and diet. Moreover, to possibly modifiable risk items for Alzheimer's disease like obesity, hypertension, type 2 diabetes mellitus, and smoking, vitamin D deficiency has been proposed to play a possible predictive role (7). Vitamin D important for maintaining cognitive functions in old age people (64). Vitamin D receptors found in CNS areas essential for memory formation and cognition and included in plaque removal (65, 66).

The link between vitamin D deficiency and cognitive defect had been studied in several systematic reviews and clinical trials, with varied results. A meta-analysis study comparing people with dementia to those without found that those with AD had lower vitamin D levels (67). A meta-analysis of cross-sectional researches reported low serum vitamin D concentrations associated with AD prevalence (68, 69). In 2004, Littlejohns et al. (32) enrolled 1658 person, of them 171 acquired dementia (102 Alzheimer disease of 171 dementia cases) for 5.6 years follow-up duration. Results showed that persons had

25(OH)D serum value less than 25 nm/L posed 2-folds risk of AD onset versus those persons with more than 50 nm/L. **Licher et al. (33)** found that subjects with vitamin D less than 25 nmol/L (defined as vitamin D deficiency) had elevated risk of having dementia versus those with more than 50 nmol/L (vitamin D sufficiency), but this finding were insignificant. Meanwhile, longitudinal studies (follow-up duration 13.3 years) showed that lower the baseline 25(OH)D values, the elevated AD developing risk. Another meta-analysis of 18,974 adults revealed that severe vitamin D deficiency (less than 10 ng/ml) increased dementia risk by 54% **(70)**. A meta-analysis of 5 cohort researches revealed that sufficient vitamin D linked with lower risk of dementia and AD **(71)**. A meta-analysis study **(72)** that included six researches **(32, 73-77)** involving 14,618 person reported significant positive associations between vitamin D deficiency (less than 20 ng/ml) and risk of AD and dementia. In elderly and young patients (30–60 years old), low vitamin D values were linked to significant losses in cognitive functioning, according to a cross-sectional analysis utilizing Pearson's correlations **(78)**. In contrary, Ulstein et al. **(79)** reported lack relation between vitamin D values and AD development. Karakis et al. **(80)** analyzed 1663 non-demented persons for 9 years follow-up duration, and reported lack link between 25(OH)D values and AD incident. In Middle East, a prospective cohort research of 13,044 people revealed that lower vitamin D values evaluated in middle age were not linked with faster cognitive deterioration during a 20 years follow-up duration **(81)**. A systematic review also found no evidence of link between cognitive deterioration and plasma 25(OH)D values **(82)**.

Current research has not fully confirmed pathophysiological processes underpinning the potential impacts of vitamin D values on risk of dementia and Alzheimer's disease, although different theories suggested. A deposition and tau protein tangles in brain tissue are two putative pathogenic pathways discovered thus far and used to identify clinical cognitive defect **(83)**. Vitamin D insufficiency causes an increase in A β deposition in the brain tissues, according to animal researches **(84)**. In human studies, vitamin D demonstrated to cause an increase in plasma A β , particularly in the elderly pearsons, implying a decrease in brain A β **(85)**. Vitamin D also affects the voltage-gated calcium channel that A β peptides target, implying that vitamin D helps restore calcium

homeostasis in neurons (86). Vitamin D reduces glutamate neurotoxicity by increasing VDR expression and acting as an antioxidant hormone (87).

Vit D can it prevent AD

Comment [A8]: This fragment is more suitable for the section "Vitamin D and neuroprotection".

Comment [A9]: This section deals more with their treatment than their prevention.

Alzheimer's disease is a neurodegenerative disease that affects memory and function. Since they have lost their autonomy, patients find it difficult to acquire enough sunlight exposure to synthesize appropriate vitamin D. Similarly, for some people, getting adequate vitamin D-rich foods can be problematic. (88). Limitation of exogenous vitamin D result in low serum vitamin D levels in Alzheimer's patients. Durk et al. investigated effect of VDR in decreasing brain soluble and insoluble amyloid β peptides in mice. They demonstrated that VDR is promising therapeutic target for Alzheimer's disease prevention and therapeutic (84).

Vitamin D supplementation proven to be effective in AD patients in a small number of researches. Annweiler et al. revealed that combining vitamin D with memantine (an AD medicine) had better effects than treating individuals with memantine only (89). Another research revealed that vitamin D intake for six months effective in mild cognitive defect cases (90). Lemire et al. revealed that memantine inhibits cognitive defect that accompanies vitamin D deficiency onset, suggests that AD cases must administered combining both vitamin D supplements and memantine (91). One of two intervention researches revealed that vitamin D intake led to enhancement in cognitive performance in cases with senile dementia (92), while second study revealed that vitamin D treatment is an independent protecting factor in Alzheimer's disease progression (93). More evidence about the link between mild cognitive impairment and vitamin D may be helpful in the early stages of dementia, like mild cognitive impairment (94). As a result, future prospective researches must look at link between vitamin D insufficiency and early stages of Alzheimer's disease and dementia.

Limitations of the review

In this review there is a lack of levels of vit D defect and severity of Alzheimer disease manifestations and associated pathology of the brain as degree of plaque deposits of the

brain. Another limitations are the studies that associated between supplements of vitamin D and decreased severity of AD after longitudinal study for long periods.

Conclusions

Alzheimer's disease is primary reason of dementia in patients over age of 65 all over the world. Even though the specific causes of AD disease have yet to be discovered, various possibilities exist to explain disease's pathophysiology. Patients with the severe form of disease will be unable to accomplish even most basic physical duties, and will be completely reliant on others for practically all of their daily activities. When illness is severe, they may have difficulty doing things like swallowing. Mostly, the cognitive defects happened in AD cases followed about twenty years of beginning of A β plaques aggregating. So, when one is suspected to have AD, they have undergone major neuron damage most of the time. Till now there is lack of cure therapy for AD. Approved used medications in AD therapy are symptoms improving therapy. They did not stop disorder progression but improve AD patients' memory decline to certain extent. Based upon current hypotheses, drugs that selectively inhibits β or γ secretase domain included in A β formation, drugs that can selectively inhibit A β accumulation, therapy that can dissolve A β plaques, neuroprotective therapy, neurogenerative therapy, tau phosphorylation inhibiting therapy, tau accumulation inhibiting therapy must be effective treatments.

Vitamin D has many functions in the treatment of dementia and AD, according to evidence from animal and cellular studies. According to cross-sectional and case-control researches, vitamin D levels in patients with cognitive defect are lower. In a small number of longitudinal studies, low vitamin D levels were connected to raised risk of cognitive defect, all-cause dementia, and Alzheimer's disease, but not in bigger studies with longer (18–20 years) follow-up periods. Clinical research examining the effects of vitamin D supplementation on cognitive outcomes have yielded conflicting results; however, a number of methodological flaws limit the applicability of these findings.

Future researches

Comment [A10]: The conclusions are not a resume of the research. They are the most important and necessary reasoning arrived at by the authors in the course of the research. They are not usually so extensive.

There is still a lack of agreement on the exact quantity of vitamin D to use and the best age to start treatment for people who are at risk. Large double-blind, randomized, placebo-controlled trials with the appropriate dosage and duration may also give conclusive results. This collection of research implies that vitamin D could be a new paradigm for dementia and Alzheimer's disease prevention and treatment.

References

1. Kumar R, Harilal S, Parambi DG, Kanthlal S, Rahman MA, Alexiou A, et al. The Role of Mitochondrial Genes in Neurodegenerative Disorders. *Current Neuropharmacology*. 2022;20(5):824-35
2. Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. *Dialogues in clinical neuroscience*. 2022
3. Cai Q, Jeong YY. Mitophagy in Alzheimer's disease and other age-related neurodegenerative diseases. *Cells*. 2020;9(1):150
4. Shen Y, editor Investigating the Mechanism of Chemical Drugs on Neurodegenerative Diseases. 2022 12th International Conference on Bioscience, Biochemistry and Bioinformatics; 2022.
5. Prabhakar P, Chandra SR, Supriya M, Issac TG, Prasad C, Christopher R. Vitamin D status and vascular dementia due to cerebral small vessel disease in the elderly Asian Indian population. *Journal of the neurological sciences*. 2015;359(1-2):108-11
6. Medhat E, Rashed L, Abdelgwad M, Aboulhoda BE, Khalifa MM, El-Din SS. Exercise enhances the effectiveness of vitamin D therapy in rats with Alzheimer's disease: emphasis on oxidative stress and inflammation. *Metabolic brain disease*. 2020;35(1):111-20
7. Anjum I, Jaffery SS, Fayyaz M, Samoo Z, Anjum S. The role of vitamin D in brain health: a mini literature review. *Cureus*. 2018;10(7)
8. Alamro AA, Alsulami EA, Almutlaq M, Alghamedi A, Alokail M, Haq SH. Therapeutic potential of vitamin D and curcumin in an in vitro model of Alzheimer disease. *Journal of Central Nervous System Disease*. 2020;12:1179573520924311

9. Peeters G, Katelekha K, Lawlor B, Demnitz N. Sex differences in the incidence and prevalence of young-onset Alzheimer's disease: A meta-analysis. *International journal of geriatric psychiatry*. 2022;37(1)
10. Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons. *Journal of Alzheimer's Disease*. 2017;57(4):975-99
11. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*. 2015;14(4):388-405
12. Firdaus Z, Singh TD. An insight in pathophysiological mechanism of Alzheimer's disease and its management using plant natural products. *Mini Reviews in Medicinal Chemistry*. 2021;21(1):35-57
13. Abeyasinghe A, Deshapriya R, Udawatte C. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. *Life Sciences*. 2020;256:117996
14. Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. *Pharmacological Reports*. 2016;68(1):127-38
15. Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. *Pharmacological reports*. 2015;67(2):195-203
16. Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H. Generation of Alzheimer disease-associated amyloid β 42/43 peptide by γ -secretase can be inhibited directly by modulation of membrane thickness. *Journal of Biological Chemistry*. 2012;287(25):21326-34
17. Alberdi E, Wyssenbach A, Alberdi M, Sánchez-Gómez MV, Cavaliere F, Rodríguez JJ, et al. Ca^{2+} -dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β -treated astrocytes and in a model of Alzheimer's disease. *Aging cell*. 2013;12(2):292-302
18. Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. *Cell Death & Differentiation*. 2021;28(2):570-90
19. Xu W, Xu Q, Cheng H, Tan X. The efficacy and pharmacological mechanism of Zn7MT3 to protect against Alzheimer's disease. *Scientific reports*. 2017;7(1):1-15

20. Jahanshahi M, Nikmahzar E, Gorgani S. Taurine can Decrease Phosphorylated Tau Protein Levels in Alzheimer's Model Rats' Brains. *Kathmandu Univ Med J*. 2021;74(2):200-4
21. Bikle D, Christakos S. New aspects of vitamin D metabolism and action—Addressing the skin as source and target. *Nature Reviews Endocrinology*. 2020;16(4):234-52
22. Bivona G, Gambino CM, Iacolino G, Ciaccio M. Vitamin D and the nervous system. *Neurological research*. 2019;41(9):827-35
23. Bivona G, Agnello L, Bellia C, Iacolino G, Scazzone C, Lo Sasso B, et al. Non-skeletal activities of vitamin D: from physiology to brain pathology. *Medicina*. 2019;55(7):341
24. Bikle DD, Patzek S, Wang Y. Physiologic and pathophysiologic roles of extra renal CYP27b1: Case report and review. *Bone reports*. 2018;8:255-67
25. Bivona G, Agnello L, Ciaccio M. The immunological implication of the new vitamin D metabolism. *Central-European journal of immunology*. 2018;43(3):331
26. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. *Frontiers in endocrinology*. 2019;10:317
27. Meyer MB, Benkusky NA, Kaufmann M, Lee SM, Onal M, Jones G, et al. A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene *Cyp27b1* essential for vitamin D3 activation. *Journal of Biological Chemistry*. 2017;292(42):17541-58
28. González-Castro TB, Blachman-Braun R, Hernández-Díaz Y, Tovilla-Zárate CA, Pérez-Hernández N, Moscardi PRM, et al. Association of vitamin D receptor polymorphisms and nephrolithiasis: a meta-analysis. *Gene*. 2019;711:143936
29. Duchaine CS, Talbot D, Nafti M, Giguère Y, Dodin S, Tourigny A, et al. Vitamin D status, cognitive decline and incident dementia: the Canadian Study of Health and Aging. *Canadian journal of public health = Revue canadienne de sante publique*. 2020;111(3):312-2110.17269/s41997-019-00290-5.
30. Manzo C, Castagna A, Palummeri E, Traini E, Cotroneo AM, Fabbo A, et al. [Relationship between 25-hydroxy vitamin D and cognitive status in older adults: the

COGNIDAGE study]. *Recenti progressi in medicina*. 2016;107(2):75-8310.1701/2152.23270.

31. Lee DH, Chon J, Kim Y, Seo YK, Park EJ, Won CW, et al. Association between vitamin D deficiency and cognitive function in the elderly Korean population: A Korean frailty and aging cohort study. *Medicine*. 2020;99(8):e1929310.1097/md.00000000000019293.
32. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology*. 2014;83(10):920-810.1212/wnl.0000000000000755.
33. Licher S, de Bruijn R, Wolters FJ, Zillikens MC, Ikram MA, Ikram MK. Vitamin D and the Risk of Dementia: The Rotterdam Study. *Journal of Alzheimer's disease : JAD*. 2017;60(3):989-9710.3233/jad-170407.
34. Ertilav E, Barcin NE, Ozdem S. Comparison of Serum Free and Bioavailable 25-Hydroxyvitamin D Levels in Alzheimer's Disease and Healthy Control Patients. *Laboratory medicine*. 2021;52(3):219-2510.1093/labmed/lmaa066.
35. Shih EJ, Lee WJ, Hsu JL, Wang SJ, Fuh JL. Effect of vitamin D on cognitive function and white matter hyperintensity in patients with mild Alzheimer's disease. *Geriatrics & gerontology international*. 2020;20(1):52-810.1111/ggi.13821.
36. Eyles DW. Vitamin D: brain and behavior. *JBMR plus*. 2021;5(1):e10419
37. Khafaei M, Sadeghi Hajiabadi M, Abdolmaleki A. Role of 1, 25-dihydroxycholecalciferol in immunological and molecular pathways involved in Multiple Sclerosis. *Central Asian Journal of Medical and Pharmaceutical Sciences Innovation*. 2021;1(2):55-66
38. Feron F, Burne T, Brown J, Smith E, McGrath J, Mackay-Sim A, et al. Developmental Vitamin D3 deficiency alters the adult rat brain. *Brain research bulletin*. 2005;65(2):141-8
39. Seyedi M, Gholami F, Samadi M, Djalali M, Effatpanah M, Yekaninejad MS, et al. The effect of vitamin D3 supplementation on serum BDNF, dopamine, and serotonin in children with attention-deficit/hyperactivity disorder. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*. 2019;18(6):496-501

40. Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J, et al. Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis. *JAMA network open*. 2019;2(12):e1917789-e
41. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing “D” ecline? *Molecular aspects of medicine*. 2008;29(6):415-22
42. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. *Trends in Endocrinology & Metabolism*. 2002;13(3):100-5
43. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation*. 2008;117(4):503-11
44. Lefebvre d'Hellencourt C, Montero-Menei CN, Bernard R, Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. *Journal of neuroscience research*. 2003;71(4):575-82
45. Lee DM, Tajar A, Ulubaev A, Pendleton N, O'Neill TW, O'Connor DB, et al. Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged and older European men. *Journal of Neurology, Neurosurgery & Psychiatry*. 2009;80(7):722-9
46. Durmaz A, Kumral E, Durmaz B, Onay H, Aslan GI, Ozkinay F, et al. Genetic factors associated with the predisposition to late onset Alzheimer's disease. *Gene*. 2019;707:212-5
47. Poduslo SE, Yin X. Chromosome 12 and late-onset Alzheimer's disease. *Neuroscience letters*. 2001;310(2-3):188-90.1016/s0304-3940(01)02130-9.
48. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. *Nature genetics*. 1998;19(4):357-60.1038/1243.
49. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. *Neurology*. 1998;50(6):1905-710.1212/wnl.50.6.1905.
50. Luedeking-Zimmer E, DeKosky ST, Nebes R, Kamboh MI. Association of the 3' UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's

disease. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003;117b(1):114-710.1002/ajmg.b.10026.

51. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. American journal of human genetics. 2009;84(1):35-4310.1016/j.ajhg.2008.12.008.

52. Gezen-Ak D, Dursun E, Ertan T, Hanağasi H, Gürvit H, Emre M, et al. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. The Tohoku journal of experimental medicine. 2007;212(3):275-8210.1620/tjem.212.275.

53. Ak DG, Kahraman H, Dursun E, Duman BS, Erensoy N, Alagöl F, et al. Polymorphisms at the ligand binding site of the vitamin D receptor gene and osteomalacia. Disease markers. 2005;21(4):191-710.1155/2005/645260.

54. Gezen-Ak D, Dursun E, Bilgiç B, Hanağasi H, Ertan T, Gürvit H, et al. Vitamin D receptor gene haplotype is associated with late-onset Alzheimer's disease. The Tohoku journal of experimental medicine. 2012;228(3):189-9610.1620/tjem.228.189.

55. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143-5610.1016/j.gene.2004.05.014.

56. Kuningas M, Mooijaart SP, Jolles J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiology of aging. 2009;30(3):466-7310.1016/j.neurobiolaging.2007.07.001.

57. Beydoun MA, Ding EL, Beydoun HA, Tanaka T, Ferrucci L, Zonderman AB. Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. The American journal of clinical nutrition. 2012;95(1):163-7810.3945/ajcn.111.017137.

58. Lehmann DJ, Refsum H, Warden DR, Medway C, Wilcock GK, Smith AD. The vitamin D receptor gene is associated with Alzheimer's disease. Neuroscience letters. 2011;504(2):79-8210.1016/j.neulet.2011.08.057.

59. Butler MW, Burt A, Edwards TL, Zuchner S, Scott WK, Martin ER, et al. Vitamin D receptor gene as a candidate gene for Parkinson disease. *Annals of human genetics*. 2011;75(2):201-1010.1111/j.1469-1809.2010.00631.x.
60. Gezen-Ak D, Alayhoğlu M, Genç G, Gündüz A, Candaş E, Bilgiç B, et al. GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features. *Neuromolecular medicine*. 2017;19(1):24-4010.1007/s12017-016-8415-9.
61. Vargas T, Bullido MJ, Martinez-Garcia A, Antequera D, Clarimon J, Rosich-Estrago M, et al. A megalin polymorphism associated with promoter activity and Alzheimer's disease risk. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. 2010;153b(4):895-90210.1002/ajmg.b.31056.
62. Wang LL, Pan XL, Wang Y, Tang HD, Deng YL, Ren RJ, et al. A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer's disease in the Chinese population. *Clinica chimica acta; international journal of clinical chemistry*. 2011;412(3-4):268-7010.1016/j.cca.2010.10.015.
63. Gezen-Ak D, Dursun E. Molecular basis of vitamin D action in neurodegeneration: the story of a team perspective. *Hormones*. 2019;18(1):17-21
64. Pérez-López FR, Chedraui P, Fernández-Alonso AM. Vitamin D and aging: beyond calcium and bone metabolism. *Maturitas*. 2011;69(1):27-36
65. Annweiler C, Schott A-M, Berrut G, Chauviré V, Le Gall D, Inzitari M, et al. Vitamin D and ageing: neurological issues. *Neuropsychobiology*. 2010;62(3):139-50
66. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid- β and preventing the amyloid- β induced alterations by vitamin D in cortical neurons. *Journal of Alzheimer's disease*. 2011;23(2):207-19
67. Zhao Y, Sun Y, Ji H-F, Shen L. Vitamin D levels in Alzheimer's and Parkinson's diseases: a meta-analysis. *Nutrition*. 2013;29(6):828-32
68. Balion C, Griffith LE, Striffler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. *Neurology*. 2012;79(13):1397-405

69. Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. *Journal of Alzheimer's disease*. 2013;37(1):147-71
70. Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, et al. Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. *BMC geriatrics*. 2017;17(1):1610.1186/s12877-016-0405-0.
71. Jayedi A, Rashidy-Pour A, Shab-Bidar S. Vitamin D status and risk of dementia and Alzheimer's disease: a meta-analysis of dose-response. *Nutritional neuroscience*. 2019;22(11):750-9
72. Chai B, Gao F, Wu R, Dong T, Gu C, Lin Q, et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer's disease: an updated meta-analysis. *BMC neurology*. 2019;19(1):28410.1186/s12883-019-1500-6.
73. Olsson E, Byberg L, Karlström B, Cederholm T, Melhus H, Sjögren P, et al. Vitamin D is not associated with incident dementia or cognitive impairment: an 18-y follow-up study in community-living old men. *The American journal of clinical nutrition*. 2017;105(4):936-4310.3945/ajcn.116.141531.
74. Knekt P, Sääksjärvi K, Järvinen R, Marniemi J, Männistö S, Kanerva N, et al. Serum 25-hydroxyvitamin d concentration and risk of dementia. *Epidemiology (Cambridge, Mass)*. 2014;25(6):799-80410.1097/ede.000000000000175.
75. Schneider AL, Lutsey PL, Alonso A, Gottesman RF, Sharrett AR, Carson KA, et al. Vitamin D and cognitive function and dementia risk in a biracial cohort: the ARIC Brain MRI Study. *European journal of neurology*. 2014;21(9):1211-8, e69-7010.1111/ene.12460.
76. Fearf C, Helmer C, Merle B, Herrmann FR, Annweiler C, Dartigues JF, et al. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(11):1207-1610.1016/j.jalz.2017.03.003.
77. Annweiler C, Le Gall D, Fantino B, Beauchet O, Tucker KL, Buell JS. 25-hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. *Neurology*. 2010;75(1):95; author reply -610.1212/WNL.0b013e3181e00ddb.

78. Darwish H, Zeinoun P, Ghusn H, Khoury B, Tamim H, Khoury SJ. Serum 25-hydroxyvitamin D predicts cognitive performance in adults. *Neuropsychiatric disease and treatment*. 2015;11:2217-2310.2147/ndt.s87014.
79. Ulstein I, Bøhmer T. Normal Vitamin Levels and Nutritional Indices in Alzheimer's Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes. *Journal of Alzheimer's disease : JAD*. 2017;55(2):717-2510.3233/jad-160393.
80. Karakis I, Pase MP, Beiser A, Booth SL, Jacques PF, Rogers G, et al. Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study. *Journal of Alzheimer's disease : JAD*. 2016;51(2):451-6110.3233/jad-150991.
81. Schneider ALC, Zhao D, Lutsey PL, Gottesman RF, Sharrett AR, Rawlings AM, et al. Serum Vitamin D Concentrations and Cognitive Change Over 20 Years: The Atherosclerosis Risk in Communities Neurocognitive Study. *Neuroepidemiology*. 2018;51(3-4):131-710.1159/000490912.
82. Barnard K, Colón-Emeric C. Extraskelatal effects of vitamin D in older adults: cardiovascular disease, mortality, mood, and cognition. *The American journal of geriatric pharmacotherapy*. 2010;8(1):4-3310.1016/j.amjopharm.2010.02.004.
83. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. *Molecular immunology*. 2011;48(14):1592-60310.1016/j.molimm.2011.04.003.
84. Durk MR, Han K, Chow EC, Ahrens R, Henderson JT, Fraser PE, et al. 1 α ,25-Dihydroxyvitamin D3 reduces cerebral amyloid- β accumulation and improves cognition in mouse models of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(21):7091-10110.1523/jneurosci.2711-13.2014.
85. Miller BJ, Whisner CM, Johnston CS. Vitamin D Supplementation Appears to Increase Plasma A β 40 in Vitamin D Insufficient Older Adults: A Pilot Randomized Controlled Trial. *Journal of Alzheimer's disease : JAD*. 2016;52(3):843-710.3233/jad-150901.
86. Gunn AP, Wong BX, Johanssen T, Griffith JC, Masters CL, Bush AI, et al. Amyloid- β Peptide A β 3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization,

and Calcium Influx in Neurons. *The Journal of biological chemistry*. 2016;291(12):6134-4510.1074/jbc.M115.655183.

87. Supriya M, Chandra SR, Prabhakar P, Prasad C, Christopher R. Vitamin D receptor (VDR) gene polymorphism and vascular dementia due to cerebral small vessel disease in an Asian Indian cohort. *J Neurol Sci*. 2018;391:84-910.1016/j.jns.2018.05.025.

88. Tobore TO. On the Etiopathogenesis and Pathophysiology of Alzheimer's Disease: A Comprehensive Theoretical Review. *Journal of Alzheimer's disease : JAD*. 2019;68(2):417-3710.3233/jad-181052.

89. Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. *Trials*. 2011;12:23010.1186/1745-6215-12-230.

90. SanMartin CD, Henriquez M, Chacon C, Ponce DP, Salech F, Rogers NK, et al. Vitamin D Increases A β 140 Plasma Levels and Protects Lymphocytes from Oxidative Death in Mild Cognitive Impairment Patients. *Current Alzheimer research*. 2018;15(6):561-910.2174/1567205015666171227154636.

91. Lemire P, Brangier A, Beaudenon M, Duval GT, Annweiler C. Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study. *The Journal of steroid biochemistry and molecular biology*. 2018;175:151-610.1016/j.jsbmb.2016.12.019.

92. Gangwar AK, Rawat A, Tiwari S, Tiwari SC, Narayan J, Tiwari S. Role of Vitamin-D in the prevention and treatment of Alzheimer's disease. *Indian journal of physiology and pharmacology*. 2015;59(1):94-9

93. Chaves M TA, Bissoni A, Rojas JI, Fernandez C, Garcia Basalo MJ, Matusevich D, Cristiano E, Golimstok A Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease. *Vertex* 2014;25(114):85–91

94. Al-Amin M, Bradford D, Sullivan RKP, Kurniawan ND, Moon Y, Han SH, et al. Vitamin D deficiency is associated with reduced hippocampal volume and disrupted structural connectivity in patients with mild cognitive impairment. *Human brain mapping*. 2019;40(2):394-40610.1002/hbm.24380.



UNDER PEER REVIEW